B M Baker1, B L Block, A C Rothchild, B D Walker. 1. Partners AIDS Research Center, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, MA 02129, USA.
Abstract
BACKGROUND: 'Elite controllers' are rare HIV-infected individuals who are able to spontaneously control HIV replication without medication, maintaining viral loads that are consistently below the limits of detection by currently available commercial assays. OBJECTIVE: To examine studies of elite controllers that may elucidate mechanisms of HIV immune control useful in designing a vaccine. METHODS: Recent literature on HIV controllers and studies that have evaluated aspects of viral and host immunology that correlate with viral control are examined. RESULTS/ CONCLUSIONS: Although many elements of innate and adaptive immunity are associated with control of HIV infection, the specific mechanism(s) by which elite controllers achieve control remain undefined. Ongoing studies of elite controllers, including those examining host genetic polymorphisms, should facilitate the definition of an effective HIV-specific immune response and guide vaccine design.
BACKGROUND: 'Elite controllers' are rare HIV-infected individuals who are able to spontaneously control HIV replication without medication, maintaining viral loads that are consistently below the limits of detection by currently available commercial assays. OBJECTIVE: To examine studies of elite controllers that may elucidate mechanisms of HIV immune control useful in designing a vaccine. METHODS: Recent literature on HIV controllers and studies that have evaluated aspects of viral and host immunology that correlate with viral control are examined. RESULTS/ CONCLUSIONS: Although many elements of innate and adaptive immunity are associated with control of HIV infection, the specific mechanism(s) by which elite controllers achieve control remain undefined. Ongoing studies of elite controllers, including those examining host genetic polymorphisms, should facilitate the definition of an effective HIV-specific immune response and guide vaccine design.
Authors: Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors Journal: Nat Immunol Date: 2002-10-07 Impact factor: 25.606
Authors: M R Betts; D R Ambrozak; D C Douek; S Bonhoeffer; J M Brenchley; J P Casazza; R A Koup; L J Picker Journal: J Virol Date: 2001-12 Impact factor: 5.103
Authors: T Harrer; E Harrer; S A Kalams; T Elbeik; S I Staprans; M B Feinberg; Y Cao; D D Ho; T Yilma; A M Caliendo; R P Johnson; S P Buchbinder; B D Walker Journal: AIDS Res Hum Retroviruses Date: 1996-05-01 Impact factor: 2.205
Authors: A Muñoz; A J Kirby; Y D He; J B Margolick; B R Visscher; C R Rinaldo; R A Kaslow; J P Phair Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1995-04-15
Authors: Maria Salgado; Gregory D Kirk; Andrea Cox; Alleluiah Rutebemberwa; Yvonne Higgins; Jacquie Astemborski; David L Thomas; Chloe L Thio; Mark S Sulkowski; Joel N Blankson Journal: AIDS Date: 2011-01-28 Impact factor: 4.177
Authors: Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman Journal: J Virol Date: 2013-12-18 Impact factor: 5.103
Authors: Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov Journal: J Virol Date: 2017-08-24 Impact factor: 5.103
Authors: Vanessa Rivera-Amill; Rakesh Kumar; Richard J Noel; Yashira Garcia; Idia V Rodriguez; Melween Martinez; Carlos A Sariol; Edmundo Kraiselburd; Marcus Iszard; Mridul Mukherji; Santosh Kumar; Luis D Giavedoni; Anil Kumar Journal: AIDS Res Hum Retroviruses Date: 2010-08 Impact factor: 2.205
Authors: Andrew L Ferguson; Jaclyn K Mann; Saleha Omarjee; Thumbi Ndung'u; Bruce D Walker; Arup K Chakraborty Journal: Immunity Date: 2013-03-21 Impact factor: 31.745
Authors: Bernard J C Macatangay; Marta E Szajnik; Theresa L Whiteside; Sharon A Riddler; Charles R Rinaldo Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240